News for BerGenBio ASA (BGBIOO.OL)

Year-End Cash: NOK 140 million, slightly above guidance.Operating Loss: NOK 151 million, below the guidance of NOK 160 million.Release Date: February 26, 2025F

Feb 26, 2025 / 09:30AM GMTOlav Hellebo - Bergenbio ASA - Chief Executive Officer Good morning. Welcome to the BerGenBio Q4 2024 presentation. I'm Olav Hellebo.

Swarm Oncology co-founded by renowned T cell therapy manufacturing expert and immunologist Professor John Campbell, and mission-driven investor, D...

PR NewswireBERGEN, Norway, Jan. 7, 2025 BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company

PR NewswireBERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical compa

BerGenBio Third Quarter Results 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Cash Raised: NOK138.9 million from warrant exercise.Total Financing Raised: Almost NOK400 million since June of last year.Cash at End of Quarter: NOK200 millio

Aug 21, 2024 / 07:45AM GMTMartin Olin - Bergenbio ASA - Chief Executive Officer (spoken in foreign language) So I'll do this in English. I'm Martin Olin, the CE

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

May 29, 2024 / 08:00AM GMTMartin Olin - Bergenbio ASA - Chief Executive Officer Good morning. My name is Martin Olin, and welcome to the quarterly report for th

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number...

There is nothing better than starting a year with looking at 15

BERGEN, Norway, Feb. 17, 2021 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AX...